论文部分内容阅读
目的探讨乳腺癌组织中环加氧化物酶-2(COX-2)、抑癌基因P53及多药耐药基因MDR-1/P-gp的表达及其相互关系。方法应用Envision免疫组织化学方法,半定量检测66例未经放、化疗的乳腺癌手术切除标本中COX-2、抑癌基因P53和MDR-1/P-gp的表达。结果 1.乳腺癌组织中COX-2、抑癌基因P53和MDR-1/P-gp的阳性表达率各为62.1%(41/66)、50%(33/66)和40.9%(27/66)。2.乳腺癌中COX-2的阳性表达与抑癌基因P53、多药耐药基因MDR-1/P-gp的阳性表达呈正相关(r分别为0.281和0.332,P<0.006)。3.抑癌基因P53的阳性表达与多药耐药基因MDR-1/P-gp的阳性表达呈正相关(r=0.277,P=0.024)。结论在乳腺癌组织中联合检测COX-2、P53和MDR-1/P-gp可以更好的指导临床乳腺癌的预后,可作为评估乳腺癌进展和判断预后的重要指标,寻找治疗乳腺癌新的作用靶点,同时对这些指标及其相关性的研究为其抑制剂在临床的应用或联合应用提供一定的分子学依据。
Objective To investigate the expression of cyclooxygenase-2 (COX-2), tumor suppressor gene P53 and multidrug resistance gene MDR-1 / P-gp in breast cancer. Methods Envision immunohistochemistry was used to detect the expression of COX-2, tumor suppressor gene P53 and MDR-1 / P-gp in 66 cases of breast cancer without operation and chemotherapy. The positive rates of COX-2, tumor suppressor gene P53 and MDR-1 / P-gp in breast cancer tissues were 62.1% (41/66), 50% (33/66) and 40.9% (27 / 66). The positive expression of COX-2 in breast cancer was positively correlated with the expression of tumor suppressor gene P53 and multidrug resistance gene MDR-1 / P-gp (r = 0.281 and 0.332, P <0.006, respectively). The positive expression of tumor suppressor gene P53 was positively correlated with the expression of multidrug resistance gene MDR-1 / P-gp (r = 0.277, P = 0.024). Conclusions Combined detection of COX-2, P53 and MDR-1 / P-gp in breast cancer can better guide the prognosis of clinical breast cancer and may be used as an important index to evaluate the progress of breast cancer and prognosis. Of the target, at the same time, the study of these indexes and their correlation provide a molecular basis for their clinical application or combination of inhibitors.